Exploiting DNA mismatch repair deficiency as a therapeutic strategy

Area of Science:

• Genomic stability and cancer biology
• DNA repair mechanisms
• Therapeutic resistance in oncology

Background:

• The DNA Mismatch repair (MMR) pathway is essential for maintaining genomic stability by correcting DNA replication errors.
• MMR deficiency is prevalent in various cancers, including Lynch syndrome-associated malignancies, and confers resistance to standard chemotherapies.
• Non-canonical functions of MMR proteins are increasingly recognized, suggesting broader roles beyond DNA repair.

Purpose of the Study:

• To review the role of MMR deficiency in cancer development and treatment resistance.
• To explore the canonical and non-canonical functions of MMR proteins.
• To discuss emerging therapeutic strategies targeting MMR-deficient tumors.

Main Methods:

• Literature review of studies on DNA Mismatch repair (MMR) in cancer.
• Analysis of research on therapeutic resistance associated with MMR deficiency.
• Synthesis of data on synthetic lethality and novel MMR regulators.

Main Results:

• MMR deficiency is a hallmark of several cancers and is associated with resistance to methylating agents, platinum compounds, and fluoropyrimidines.
• Emerging evidence highlights non-canonical roles for MMR proteins, expanding their significance in cancer.
• Synthetic lethal interactions with MMR loss present potential therapeutic vulnerabilities.

Conclusions:

• Targeting both canonical and non-canonical MMR functions offers promising avenues for novel cancer therapies.
• Exploiting MMR deficiency could lead to more effective treatments for MMR-deficient tumors.
• Further research into MMR regulators and synthetic lethality is crucial for clinical advancement.